National Energy Services Reunited Corp Ordinary Shares vs Twist Bioscience Corp — how do they compare? National Energy Services Reunited Corp Ordinary Shares trades at $19.71 (market cap $2.12B), while Twist Bioscience Corp trades at $146 (market cap $10.03B). The key difference: Twist Bioscience Corp is far larger — about 4.7× National Energy Services Reunited Corp Ordinary Shares's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, National Energy Services Reunited Corp Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Energy Services Reunited Corp Ordinary Shares for 0 Days and Twist Bioscience Corp for 27 Days on average.
| NESR | TWST | |
|---|---|---|
Market Cap | $2.12B | $10.03B |
Volume | 3,257,316 | 1,528,940 |
Sector | Energy | Health |
52-Week High | $36.31 | $205.00 |
52-Week Low | $10.41 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $2.24B | $9.96B |
Signals from Pluang's Aura AI — not financial advice
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
TWST trades at $148.16, down 2.44% today, with a bullish technical signal but negative earnings trends. Recent news highlights its role in Eli Lilly's AI drug discovery platform, driving investor optimism. Revenue growth is strong, reaching $376.57M in 2025, but net losses persist, with a margin of -20.63%. The stock faces resistance near $154, with support at $146.
Outlook is mixed: analyst consensus is bullish with a $153.70 price target, but profitability challenges and cash flow deficits pose risks. The AI collaboration offers growth potential, yet execution and margin improvement are critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →